BMS HCV drug hit by German value assessor
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's first in class Daklinza (daclatasvir) gives no proven added benefit for hepatitis C patients compared to other therapies, according to the German HTA, IQWiG. The firm has failed to come up with the data needed to prove the drug is better than dual therapy with peginterferon alfa and ribavirin, or triple therapy with peginterferon alfa and ribavirin plus a protease inhibitor (boceprevir or telaprevir), it said.